Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease.’ The study aims to evaluate the effectiveness and safety of the drug retatrutide in individuals with obesity and cardiovascular disease over approximately 113 weeks.
Intervention/Treatment: The study tests retatrutide, administered subcutaneously, against a placebo. Retatrutide is intended to treat severe obesity in patients with cardiovascular disease.
Study Design: This interventional study uses a randomized, parallel assignment model with double masking for both participants and investigators. The primary purpose is treatment-focused, aiming to assess the drug’s efficacy and safety.
Study Timeline: The study began on May 30, 2023, and the latest update was submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
Market Implications: This study’s progress could significantly influence Eli Lilly’s stock performance, as successful results may enhance investor confidence and market position, especially in the competitive obesity treatment market. Investors should monitor developments closely, considering potential impacts on both Eli Lilly and its competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.